Homogeneous Photometry V: The Globular Cluster NGC 4147

New BVRI broad-band photometry and astrometry are presented for the globular cluster NGC 4147, based upon measurements derived from 524 ground-based CCD images mostly either donated by colleagues or retrieved from public archives. We have also reanalysed five exposures of the cluster obtained with WFPC2 on the Hubble Space Telescope in the F439W and F555W (B and V) filters. We present calibrated color-magnitude and color-color diagrams. Analysis of the color-magnitude diagram reveals morphogical properties generally consistent with published metal-abundance estimates for the cluster, and an age typical of other Galactic globular clusters of similar metallicity. We have also redetermined the periods and mean magnitudes for the RR Lyrae variables, including a new c-type variable reported here for the first time. Our data do not show clear evidence for photometric variability in candidate V18, recently reported by Arellano Ferro et al. (2004). These observations also support the non-variable status of candidates V5, V9, and V15. The union of our light-curve data with those of Newburn (1957), Mannino (1957) and Arellano Ferro et al. (op. cit.) permits the derivation of significantly improved periods. The mean periods and the Bailey period-amplitude diagrams support the classification of the cluster as Oosterhoff I despite its predominantly blue horizontal branch. The number ratio of c- to ab-type RR Lyrae stars, on the other hand, is unusually high for an Oosterhoff I cluster. The calibrated results have been made available through the first author's web site.Comment: 30 pages, 30 figures. PASP, in press. Uses 11/2004 version of emulateapj (included). For the full-resolution preprint, the reader is encouraged to download the ps file (123 pages, manuscript format) available at http://cadcwww.hia.nrc.ca/stetson/NGC4147/ms.ps.gz, or the pdf file (30 pages, preprint format) available at http://www.astro.puc.cl/~mcatelan/N4147/full-res.pd

Combined resistance to oxidative stress and reduced antenna size enhance light-to-biomass conversion efficiency in Chlorella vulgaris cultures

Background: Microalgae are efficient producers of lipid-rich biomass, making them a key component in developing a sustainable energy source, and an alternative to fossil fuels. Chlorella species are of special interest because of their fast growth rate in photobioreactors. However, biological constraints still cast a significant gap between the high cost of biofuel and cheap oil, thus hampering perspective of producing CO2-neutral biofuels. A key issue is the inefficient use of light caused by its uneven distribution in the culture that generates photoinhibition of the surface-exposed cells and darkening of the inner layers. Efficient biofuel production, thus, requires domestication, including traits which reduce optical density of cultures and enhance photoprotection. Results: We applied two steps of mutagenesis and phenotypic selection to the microalga Chlorella vulgaris. First, a pale-green mutant (PG-14) was selected, with a 50% reduction of both chlorophyll content per cell and LHCII complement per PSII, with respect to WT. PG-14 showed a 30% increased photon conversion into biomass efficiency vs. WT. A second step of mutagenesis of PG-14, followed by selection for higher tolerance to Rose Bengal, led to the isolation of pale-green genotypes, exhibiting higher resistance to singlet oxygen (strains SOR). Growth in photobioreactors under high light conditions showed an enhanced biomass production of SOR strains with respect to PG-14. When compared to WT strain, biomass yield of the pale green+ sor genotype was enhanced by 68%. Conclusions: Domestication of microalgae like Chlorella vulgaris, by optimizing both light distribution and ROS resistance, yielded an enhanced carbon assimilation rate in photobioreactor

Simulation-Based Estimates of Effectiveness and Cost-Effectiveness of Smoking Cessation in Patients with Chronic Obstructive Pulmonary Disease

International audienceBACKGROUND: The medico-economic impact of smoking cessation considering a smoking patient with chronic obstructive pulmonary disease (COPD) is poorly documented. OBJECTIVE: Here, considering a COPD smoking patient, the specific burden of continuous smoking was estimated, as well as the effectiveness and the cost-effectiveness of smoking cessation. METHODS: A multi-state Markov model adopting society's perspective was developed. Simulated cohorts of English COPD patients who are active smokers (all severity stages combined or patients with the same initial severity stage) were compared to identical cohorts of patients who quit smoking at cohort initialization. Life expectancy, quality adjusted life-years (QALY), disease-related costs, and incremental cost-effectiveness ratio (ICER: £/QALY) were estimated, considering smoking cessation programs with various possible scenarios of success rates and costs. Sensitivity analyses included the variation of model key parameters. PRINCIPAL FINDINGS: At the horizon of a smoking COPD patient's remaining lifetime, smoking cessation at cohort intitialization, relapses being allowed as observed in practice, would result in gains (mean) of 1.27 life-years and 0.68 QALY, and induce savings of -1824 £/patient in the disease-related costs. The corresponding ICER was -2686 £/QALY. Smoking cessation resulted in 0.72, 0.69, 0.64 and 0.42 QALY respectively gained per mild, moderate, severe, and very severe COPD patient, but was nevertheless cost-effective for mild to severe COPD patients in most scenarios, even when hypothesizing expensive smoking cessation intervention programmes associated with low success rates. Considering a ten-year time horizon, the burden of continuous smoking in English COPD patients was estimated to cost a total of 1657 M£ while 452516 QALY would be simultaneously lost. CONCLUSIONS: The study results are a useful support for the setting of smoking cessation programmes specifically targeted to COPD patients

Status of the LUX Dark Matter Search

The Large Underground Xenon (LUX) dark matter search experiment is currently being deployed at the Homestake Laboratory in South Dakota. We will highlight the main elements of design which make the experiment a very strong competitor in the field of direct detection, as well as an easily scalable concept. We will also present its potential reach for supersymmetric dark matter detection, within various timeframes ranging from 1 year to 5 years or more.Comment: 4 pages, in proceedings of the SUSY09 conferenc

After LUX: The LZ Program

The LZ program consists of two stages of direct dark matter searches using liquid Xe detectors. The first stage will be a 1.5-3 tonne detector, while the last stage will be a 20 tonne detector. Both devices will benefit tremendously from research and development performed for the LUX experiment, a 350 kg liquid Xe dark matter detector currently operating at the Sanford Underground Laboratory. In particular, the technology used for cryogenics and electrical feedthroughs, circulation and purification, low-background materials and shielding techniques, electronics, calibrations, and automated control and recovery systems are all directly scalable from LUX to the LZ detectors. Extensive searches for potential background sources have been performed, with an emphasis on previously undiscovered background sources that may have a significant impact on tonne-scale detectors. The LZ detectors will probe spin-independent interaction cross sections as low as 5E-49 cm2 for 100 GeV WIMPs, which represents the ultimate limit for dark matter detection with liquid xenon technology.Comment: Conference proceedings from APS DPF 2011. 9 pages, 6 figure

High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial

<p>Abstract</p> <p>Background</p> <p>High frequency chest wall oscillation (HFCWO) is used for airway mucus clearance. The objective of this study was to evaluate the use of HFCWO early in the treatment of adults hospitalized for acute asthma or chronic obstructive pulmonary disease (COPD).</p> <p>Methods</p> <p>Randomized, multi-center, double-masked phase II clinical trial of active or sham treatment initiated within 24 hours of hospital admission for acute asthma or COPD at four academic medical centers. Patients received active or sham treatment for 15 minutes three times a day for four treatments. Medical management was standardized across groups. The primary outcomes were patient adherence to therapy after four treatments (minutes used/60 minutes prescribed) and satisfaction. Secondary outcomes included change in Borg dyspnea score (≥ 1 unit indicates a clinically significant change), spontaneously expectorated sputum volume, and forced expired volume in 1 second.</p> <p>Results</p> <p>Fifty-two participants were randomized to active (n = 25) or sham (n = 27) treatment. Patient adherence was similarly high in both groups (91% vs. 93%; p = 0.70). Patient satisfaction was also similarly high in both groups. After four treatments, a higher proportion of patients in the active treatment group had a clinically significant improvement in dyspnea (70.8% vs. 42.3%, p = 0.04). There were no significant differences in other secondary outcomes.</p> <p>Conclusions</p> <p>HFCWO is well tolerated in adults hospitalized for acute asthma or COPD and significantly improves dyspnea. The high levels of patient satisfaction in both treatment groups justify the need for sham controls when evaluating the use of HFCWO on patient-reported outcomes. Additional studies are needed to more fully evaluate the role of HFCWO in improving in-hospital and post-discharge outcomes in this population.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00181285">NCT00181285</a></p